. intolerance). Ibrutinib is the current gold regular therapy for patients with relapsed/refractory condition, based on the outcomes of numerous period I-III trials, 115–119 but this is also changing for 2 major factors: (i) an ever-increasing proportion of patients at this time receive ibrutinib as frontline therapy; and (ii) several https://mbl7742739.bloggadores.com/30934433/the-fact-about-situs-judi-mbl77-that-no-one-is-suggesting